MAZINDOL

- Everything we could find out about it

Home ] [ Controlled Substances ] [ Stimulants ]

Created Sep 2019 | Updated Nov 2020

MAZINDOL

  • [SANOREX]
  • [MAZANOR]

DEA CODE 1605: Schedule 4

Mazindol is an amphetamine-like medicine which was developed by Sandoz in 1967 and approved by FDA for the treatment of obesity and Duchenne muscular dystrophy under the names Sanorex and Mazanor. The exact mechanism of action is unknown, but possibly involves the stimulation of beta-adrenergic receptors and inhibition of monoamine reuptake. Both Sanorex and Mazanor were withdrawn from the market by reason other than safety. NLS Pharma now is developing mazindol for Attention Hyperactivity Disorder in adults (phase II).

What is it Supposed to do:
Mazindol stimulates the satiety (feeling of fullness) center in the hypothalamus and limbic regions of the brain, where appetite and hunger are controlled. In order to work, mazindol must he used in addition to a low-calorie eating plan,behavior modification, and a physical exercise program. Nevertheless, weight loss may be only short-term, especially after the drug is discontinued. To maintain weight loss or to continue to lose additional weight after stopping mazindol, it is necessary to follow a sensible eating plan and an exercise program.

Side Effects:
Although mazindol is not an amphetamine, it brings about a lot of the same side effects, including nervousness; restlessness; insomnia; euphoria; and overstimulation. Less frequent side effects include high blood pressure; heart palpitations; drowsiness or sedation; dizziness; tremors; headache; dry mouth; nausea; vomiting; diarrhea; rash; itching; hair loss; muscle pain; sweating; chills; blurred vision; fever; changes in sex drive; urinary retention; testicular pain; and weakness.

Mazindol, like other appetite suppressants, often causes dry mouth, which can increase the chance of developing gum disease and dental cavities. Special attention to oral hygiene, including use of sugarless gum and sugarless hard candies, drinking lots of water, or sucking on ice chips, is recommended while taking these drugs.

It's an Appetite Suppressant:
Although this medicine is not an amphetamine, it has many amphetamine-like effects. It suppresses appetite by working on specific areas in the brain, though studies have shown that appetite suppressants are more effective when combined with behavior therapy than when they are taken alone. Each dose of Mazindol works for 8 to 15 hours.

Mazindol Special Information
Do not take any appetite suppressant for more than 12 weeks as part of a weight-control program, and take it only under a doctor's supervision. This medicine will not reduce body weight by itself. You must limit or modify your diet and follow your exercise regimen (if applicable). Appetite suppressants often cause dry mouth, which increases the chances of dental cavities and gum disease. Pay special attention to oral hygiene if you are taking this medicine. The dry mouth usually can be relieved with sugarless candy, gum, or ice chips.

Pregnancy/Breast-feeding
Studies have shown that large doses of Mazindol may damage an unborn baby. All appetite suppressants, including Mazindol, should be avoided by women who are or could become pregnant. In cases where this drug is considered essential by your doctor, its potential benefits must be weighed against its possible hazards. It is not known if Mazindol passes into breast milk. Nursing mothers should not take any appetite suppressant.

Seniors:
Older adults should not take this medicine unless prescribed by a doctor. It can aggravate diabetes or high blood pressure, conditions common in older adults.

Children:
Although there have been some clinical trials of mazindol in obese children, its safety and efficacy in pediatric patients have not been established and the drug is not recommended for use in children younger than 12 years of age.

What is the most important information I should know about mazindol?
Use caution when driving, operating machinery, or performing other hazardous activities. Mazindol may cause dizziness, blurred vision, or restlessness, and it may hide the symptoms of extreme tiredness. If you experience these effects, avoid hazardous activities.

Mazindol is habit forming. You can become physically and psychologically dependent on this medication, and withdrawal effects may occur if you stop taking it suddenly after several weeks of continuous use. Talk to your doctor about stopping this medication gradually.

What should I avoid while taking Mazindol?
Use caution when driving, operating machinery, or performing other hazardous activities.

Mazindol may cause dizziness, blurred vision, or restlessness, and it may hide the symptoms of extreme tiredness.

If you experience these effects, avoid hazardous activities.

Interactions:

Drug Interactions (169) Alcohol/Food Interactions (3) Disease Interactions (14)


What other drugs will affect Mazindol?
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.

Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.

Mazindol may reduce the effects of guanethidine (Ismelin). This could lead to an increase in blood pressure. Tell your doctor if you are taking guanethidine.

Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as:

  • amitriptyline (Elavil)
  • amoxapine (Asendin)
  • doxepin (Sinequan)
  • nortriptyline (Pamelor)
  • imipramine (Tofranil)
  • clomipramine (Anafranil)
  • protriptyline (Vivactil)
  • desipramine (Norpramin)
These drugs may decrease the effects of mazindol.

Drugs other than those listed here may also interact with mazindol. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.

A total of 169 drugs are known to interact with Mazindol.

  • 43 major drug interactions
  • 125 moderate drug interactions
  • 3 minor drug interactions

What are the Drug Interactions of Mazindol?

  • Mazindol may have an additive effect with other weight loss drugs that act on the brain.
  • Severe high blood pressure may occur in patients taking monoamine oxidase inhibitors (MAO inhibitors). Therefore, a gap of at least 14 days should be maintained between the two drugs.
  • The intake of mazindol by patients taking lithium may result in lithium toxicity.
  • The dose of diabetes medications may have to be altered in patients taking mazindol.
  • Antidepressant drugs may reduce the effects of mazindol.

Mazindol is not currently available in the United States or the European Union. It has received an orphan drug status in the European Union for the treatment of narcolepsy, a condition that results in an irresistible desire to sleep.

India: Teronac tablet. International: Sanorex, Mazanor, Mazindol

When not to use Mazindol:
Hypersensitivity to Mazindol is a contraindication. In addition, Mazindol should not be used if you have the following conditions:

  • Glaucoma
  • Hardening of the arteries
  • Heart disease
  • High blood pressure
  • History of drug or alcohol abuse

What's bad about it?
You can only take this drug for a short while before you notice a lack of results. Even those that rated it as having positive results also tended to find the rate of anxiety and side effects to greatly outweigh any benefits. This drug is a schedule 4 drug in the US and there are many risks involved in taking in a stimulant as strong as this one. By changing the patterns in your brain there is a high risk of emotional imbalance and rate of physical discomfort. In fact the side effects of the drugs lead to just that, a complete change of quality of life in the negative. There is also the fact that this drug is habit forming and it can cause even greater side effects after addictions are formed. When taking a habit forming drug there is great risk of a reduced quality of life. Many of times the addiction becomes a mental and physical problem that completely overwhelms the body. This drug is discontinued in most markets due to safety concerns and its ability to cause major detrimental physical changes within the body. Though one study showed positive weight loss it is important to recall even the manufacturer states it is intended for only short term use and that long term use is highly not recommended.

When you still have to diet, exercise and work hard to get results then you are forced to raise question as to the effectiveness of a drug. This drug is a hardcore stimulant that is similar to hard drugs like amphetamine. The fact there is only short term results with the potential to be habit forming is much too detrimental for anyone to take in. There is a reason this drug ceases to exist in markets today without a very unique form of muscular dystrophy. The negatives greatly outweigh the benefits and the science behind it is a clear picture of this.

Overdose Symptoms:
Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.

Mazindol in current ADHD Study:
The purpose of this study is to determine whether a controlled release formulation of mazindol is more effective than a placebo in the treatment of Attention Hyperactivity Disorder (ADHD) in adults.

(2017 Study) Narcolepsy drug suggests ADHD is a sleep disorder:
A DRUG normally used to treat narcolepsy and excessive daytime sleepiness also seems to improve symptoms of attention deficit hyperactivity disorder (ADHD) symptoms. The finding supports the idea that ADHD might be a sleep disorder. Mazindol mimics the effects of a brain chemical called orexin, which modulates wakefulness and appetite. It works as a stimulant to keep us awake, and is lacking in people with narcolepsy, who tend to fall asleep at inappropriate times. Mazindol is the first new ADHD drug for decades to work in a novel way, says Efron. "Since mazindol acts on a different neurochemical pathway, it could be useful for those who don't respond to existing treatments." However, although mazindol improved many ADHD symptoms, it did not boost the quality of the volunteers' sleep, nor reduce the daytime sleepiness they experienced. The team is planning larger trials and other experiments to better understand how the drug might be working.

(1986 Study) Mazindol and Duchenne Muscular Dystrophy:
A Brazilian scientist has found a drug that appears to slow the deterioration that typifies Duchenne muscular dystrophy, an invariably fatal disease that afflicts about 20,000 boys in the United States at any one time. However, there is a catch: The drug has the unwanted effect of stunting the growth of children who receive it. It is unknown why diminishing growth hormone in growing boys with Duchenne muscular dystrophy appears to slow progression of the disease. A typical Duchenne patient begins a very rapid decline in muscle function at about age 7. She said that in the 16 years she has been studying muscular dystrophy families in Brazil, many patients have said that they would be willing to risk a drug trial if it meant that they might live another year or two.

HRES PDF Mazindol

Caymanchem PDF Mazindol

Developed in the 1960s. Mazindol is used in short-term treatment of obesity. Appetite reducing effect tends to decrease after a few weeks of treatment. Mazindol is not currently available as a commercially marketed and FDA regulated prescription agent for the treatment of obesity. As of 2016 mazindol was being studied in clinical trials for attention-deficit hyperactivity disorder.

  
What should I Know Regarding Pregnancy, Nursing and Administering Mazindol Oral to Children or the Elderly? - Sorry, we have no data available. Please contact your doctor or pharmacist.
Thursday April 25, 2013 - webmd.com

NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy - Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and ...
Sunday January 29, 2023 - finance.yahoo.com

NLS Pharma receives Israeli patent for mazindol to treat ADHD - Now read: BioLineRX anti-tumor vaccine shows promise in early-stage trial Like us on Facebook to see similar stories Please give an overall site rating: ...
Tuesday December 20, 2022 - msn.com

Selected Inhalation Anesthetic Agents/Sympathomimetics Interactions - Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious. These medicines may interact and cause very harmful effects.
Thursday October 19, 2017 - webmd.com

NLS Pharmaceutics Stock (NASDAQ:NLSP), Quotes and News Summary - NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on ...
Thursday March 04, 2021 - benzinga.com

Latest Press Releases - To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...
Thursday January 26, 2023 - seekingalpha.com

Maxim Group Reaffirms Their Buy Rating on NLS Pharmaceutics (NLSP) - NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. The company focuses ...
Tuesday January 24, 2023 - markets.businessinsider.com

NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy - "The unique mechanism of action of Mazindol ER sets it apart from agents ... comparable results to patients treated with active drug in the Phase 2 study. Those results demonstrated further ...
Sunday January 29, 2023 - benzinga.com

NLS Pharmaceutics AG: NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience for the Treatment of Narcolepsy - "The unique mechanism of action of Mazindol ER sets it apart from agents ... comparable results to patients treated with active drug in the Phase 2 study. Those results demonstrated further ...
Sunday January 29, 2023 - finanznachrichten.de

  
Stimulants | Link to this page

Home ] [ Controlled Substances ] [ Sources ]


· Controlled Substances
· Stimulants
· Mazindol